Jasper Ridge Partners’s RAPT Therapeutics RAPT Stock Holding History

Jasper Ridge Partners’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,706	Closed	-$55.7K	–	149
2025 Q1	$55.7K	Hold	5,706	–	–	﹤0.01%	141
2024 Q4	$72.1K	Hold	5,706	–	–	﹤0.01%	139
2024 Q3	$91.8K	Hold	5,706	–	–	﹤0.01%	136
2024 Q2	$139K	Hold	5,706	–	–	﹤0.01%	135
2024 Q1	$410K	Hold	5,706	–	–	0.01%	109
2023 Q4	$1.13M	Hold	5,706	–	–	0.05%	83
2023 Q3	$759K	Hold	5,706	–	–	0.04%	87
2023 Q2	$854K	Hold	5,706	–	–	0.04%	85
2023 Q1	$838K	Hold	5,706	–	–	0.04%	90
2022 Q4	$904K	Hold	5,706	–	–	0.05%	82
2022 Q3	$1.1M	Hold	5,706	–	–	0.07%	79
2022 Q2	$833K	Hold	5,706	–	–	0.05%	88
2022 Q1	$1M	Hold	5,706	–	–	0.05%	86
2021 Q4	$1.68M	Hold	5,706	–	–	0.06%	82
2021 Q3	$1.42M	Buy	+5,706	New	+$1.51M	0.06%	93

Other funds holding RAPT

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Jasper Ridge Partners's RAPT Position: Q2 2025 in Review

Jasper Ridge Partners sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 5,706 shares — an estimated $55.7K sold.

Jasper Ridge Partners first reported a position in RAPT in Q3 2021 and held it in 15 quarters. The position peaked at $1.68M in Q4 2021. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

Jasper Ridge Partners reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
Jasper Ridge Partners sold 5,706 RAPT Therapeutics shares in Q2 2025, an estimated $55.7K.
Jasper Ridge Partners first reported a position in RAPT Therapeutics in Q3 2021 and held it in 15 quarters.
Jasper Ridge Partners's RAPT Therapeutics position peaked at $1.68M in Q4 2021.
50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on Jasper Ridge Partners's 13F filing for Q2 2025, filed 14 Aug 2025.